New findings reveal Syfovre may protect central vision in macular degeneration patients, delaying vision loss and enhancing treatment strategies.

In July 2025, Novartis Pharmaceuticals conducted a study is to assess the effect of Iptacopan to prevent conversion of early ...

Susvimo is the only continuous delivery treatment to provide reliable, long-term vision outcomes in nAMD, the leading cause ...

Roche’s Susvimo maintains vision over five years with two refills per year in people with neovascular age-related macular degeneration: Basel Monday, August 4, 2025, 11:00 Hrs [ ...

Roche’s Genentech has reported new five-year data from the Phase III Portal trial, confirming the safety, durability, and ...

Basel: Roche has announced new, five-year efficacy, safety and durability data from the Phase III Portal study, a long-term ...

The eye of the apple snail is unusually similar to a human eye—but, unlike human eyes, it can regrow itself if injured ...

Ophthalmology Times connects eye care professionals with surgery, imaging, gene therapy, & diagnostic advances to enhance clinical and patient care.

Pavblu, an Eylea HD biosimilar, shows stable vision outcomes and minimal side effects in real-world use, promising a reliable ...

LONG BEACH, Calif. -- Concomitant treatment with drugs for geographic atrophy (GA) and neovascular macular degeneration (nAMD ...